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osting by EAbstract Background: Paraoxonase 1 (PON1) is reported to have antioxidant and cardioprotec-
tive properties. Recently, an association of glutamine (Gln) or type A/arginine (Arg) or type B poly-
morphism at position 192 of PON1 gene has been suggested with coronary artery disease (CAD)
among patients with diabetes mellitus (DM). However, conﬂicting results have also been reported.
Objectives: To investigate the relationship between PON1 gene (Gln192–Arg) polymorphism and
the presence, extent and severity of CAD in type 2 DM.
Methods: The study comprised 180 patients recruited from those undergoing coronary angiogra-
phy for suspected CAD, who were divided according to the presence or absence of CAD and
DM into four groups: Group I (n= 40 patients) nondiabetic subjects without CAD, Group II
(n= 45 patients) diabetic patients without CAD, Group III (n= 47 patients) nondiabetic patients
with CAD and Group IV (n= 48 patients) diabetic patients with CAD. PON1(Gln192–Arg) geno-
type was assessed using polymerase chain reaction (PCR) followed by AlwI digestion.
Results: The frequency of Gln allele (type A) was signiﬁcantly higher in Group I and Group II
compared to Group III and Group IV (62.5%, 60% vs. 38.3%, 31.25%, respectively, p< 0.001)
while the frequency of Arg allele (type B + type AB) was signiﬁcantly higher in ischemic groups11 Yossef Street from Talaat




tian Society of Cardiology.
lsevier
56 M.F. Elnoamany et al.(III and IV) compared to nonischemic groups (I and II) (61.7%, 68.75% vs. 37.5%, 40%, respec-
tively, p< 0.001). Patients with CAD and DM (Group IV) have signiﬁcantly higher severity score
and vessel score than those with CAD only (Group III) (9.7 ± 2.97, 2.44 ± 0.56 vs. 6.99 ± 3.71,
1.67 ± 0.89, respectively, p< 0.001) Patients with vessel score 3 had signiﬁcantly higher severity
score and higher Arg allele frequency than patients with vessel score 2, the latter group had also
signiﬁcantly higher severity score and Arg allele frequency than patients with vessel score 1
(8.9 ± 2.79 vs. 5.21 ± 2.13 and 80.49% vs. 67.86%), (5.21 ± 2.13 vs. 3.11 ± 0.89 and 67.86%
vs. 53.85%), p< 0.001 for all. In multivariate logistic regression analysis of different variables
for prediction of CAD, age [OR 2.99, CI (1.11–10.5), p< 0.01], smoking [OR 4.13,
CI (1.37–11.7), p< 0.001], low-density lipoprotein (LDL) cholesterol > 100 mg/dL [OR 4.31, CI
(1.25–12.5), p< 0.001], high-density lipoprotein (HDL) cholesterol < 40 mg/dL [OR 5.11, CI
(1.79–16.33), p< 0.001] and PON1 192 Arg allele [OR 4.62, CI (1.67–13.57), p< 0.001] were sig-
niﬁcantly independent predictors of CAD.
Conclusion: Arg allele of PON1 192 gene polymorphism is an independent risk factor for CAD and
is associated not only with the presence of CAD but also with its extent and severity and its impact
is clearly more pronounced in diabetic patients.
ª 2012 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Diabetes mellitus (DM) is a major risk factor for the develop-
ment of coronary artery disease (CAD), which is one of the
leading causes of morbidity and mortality in developed coun-
tries.1,2 In addition to the traditional cardiovascular risk fac-
tors, many previous studies suggested that there may be a
genetic predisposition.3,4 Many genes are likely to be involved
in the pathogenesis of CAD, including those involved in lipo-
protein metabolism.5
Human paraoxonase 1/arylesterase (PON1) is an HDL-
associated Ca2+ dependent glycoprotein (lactonase) which
possesses antioxidant and anti-atherogenic properties through
its ability to hydrolyze paraoxon, the active toxic metabolite of
the organophosphate parathion and exclusively bound to
HDL in human plasma and has been shown to reduce the
accumulation of lipid oxidation products on LDL6, thus pre-
venting the transformation of LDL into atherogenic particles.7
The human serum paraoxonase is a 43- to 45-kD protein. Its
gene is located at q21 to q22 on the long arm of chromosome
7.8 The amino acid sequence of paraoxonase is highly con-
served among animal species, suggesting an important meta-
bolic role for this enzyme.9 Human serum paraoxonase
activity toward paraoxon shows large interindividual variation
and underlies tight genetic control. The molecular basis of this
variation and decreased PON1 activity is a polymorphism in
the coding region of the gene, resulting in an amino acid sub-
stitution glutamine (Gln)/arginine (Arg) in position 192.10,11
Recently, the presence of the (Gln192–Arg) polymorphism in
the PON1 gene was reported to be an independent risk factor
for CHD in a French Caucasian population and Japanese11
patients with type 2 diabetes and in a North American general
population12 but could not be conﬁrmed in Finnish,13
Japanese,14 and Chinese15 CAD patients, mostly without dia-
betes.
2. Aim of the work
To investigate the relationship between PON1 gene polymor-
phism and the presence, extent and severity of CAD in type
2 DM.3. Patients and methods
3.1. Study population
The study comprised 180 patients recruited from those under-
going coronary angiography for suspected CAD, who were di-
vided according to the presence or absence of CAD and DM
into four groups: Group I (n= 40 patients) nondiabetic sub-
jects without CAD, Group II (n= 45 patients) diabetic pa-
tients without CAD, Group III (n= 47 patients) nondiabetic
patients with CAD and Group IV (n= 48 patients) diabetic
patients with CAD.
The study was performed prospectively in the period from
September 2009 to June 2011.
The study was approved by the appropriate Institutional
Review Board and Institutional Ethical Committee for Human
Research. All study subjects provided written informed con-
sent regarding the study procedures.
Diabetes mellitus (DM) was diagnosed according to World
Health Organization (WHO) and the American Diabetes Asso-
ciation (ADA)16–18 as fasting blood glucoseP 126 mg/dL
(P7.0 mmol/L) or 2 h post-load plasma glucoseP 200 mg/dL
(P11.1 mmol/L) or random plasma glucoseP 200 mg/dL.
3.1.1. Inclusion criteria
Patients included in the study are those undergoing diagnostic
coronary angiography for suspected ischemic heart disease
with one or more of the following:
– Typical chest pain.
– Electrocardiographic (ECG) changes suggesting CAD.
– Previous admission to hospital by CAD.
– Previous cardiac interventions e.g. percutaneous coronary
intervention (PCI), coronary artery bypass graft (CABG).
– Other investigations suggesting CAD such as, positive exer-
cise stress test, positive myocardial perfusion scanning or
echocardiographic regional wall motion abnormality sug-
gesting CAD.
For each patient the following was done:
(1) Complete history taking.
(2) Thorough clinical evaluation.
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(4) Conventional echocardiographic examination: Echocar-
diography was performed with the patient in the left lateral
decubitus position. The equipment used was Vivid S 5 system.
Measurements were performed according to the recommenda-
tions of the American Society of Echocardiography19 with the
use of the long axis parasternal, apical 4, 5 and 2-chamber
views. All patients underwent conventional M-mode and 2-D
echocardiographic examination. Visual assessment of regional
wall motion was performed. End-systolic volume, end-diastolic
volume (by manual tracing of endocardial borders) and ejec-
tion fraction of each ventricle was calculated using Simpson’s
rule.20 Conventional (continuous-wave and color) Doppler
valvular ﬂow was determined.
(5) Angiographic analysis: Diagnostic coronary angiogra-
phy (CA) was carried out in all patients using Judkins tech-
nique. Quantitative analysis of coronary arteries was
performed with the computer-assisted coronary angiography
analysis system. End-diastolic frames from each arteriogram
were selected for analysis.21 The percentage diameter stenosis
(DS) was assessed in different projections and the highest value
of each lesion was chosen. Images of the coronary tree were
obtained with the digital Philips set system and reviewed by
an experienced cardiologist who had no knowledge of the pa-
tients’ biochemical results to assess the extent and severity of
CAD and morphology of all coronary artery stenoses.
The coronary tree was divided into 16 segments as
follows22:
– The left main coronary artery (LMCA) as one segment.
– The left anterior descending (LAD) artery was divided into:
proximal, mid, distal segments beside two diagonals Dl and
D2.
– The left circumﬂex artery (LCX) artery was divided into:
proximal, mid, distal segments beside two marginal
branches OMl and OM2.
– The right coronary artery (RCA) was divided into: proxi-
mal, mid, distal segments beside posterior descending artery
(PDA) and posterolateral (PL) branch.
Coronary angiograms were scored according to:
1-Vessel score23: This was the number of vessels with a sig-
niﬁcant stenosis (50% or greater reduction in lumen diameter).
Degree of stenosis was deﬁned as the greatest percentage
reduction of luminal diameter in any view compared with
the nearest normal segment and was determined visually.
Scores ranged from 0 to 3, depending on the vessels involved.
Left main artery stenosis was scored as single vessel disease.23
2-Severity score24: the coronary circulation was divided into
eight proximal segments. Disease in the distal segments was
not considered because of difﬁculty in quantitating the severity
of lesions in these areas. The eight proximal segments scored
included the left main coronary artery, the left anterior
descending artery (LAD) up to the junction of the middle
and distal thirds of the vessel, the proximal third of the major
septal branch of the LAD, the proximal third of the major
diagonal branch of the LAD, the left circumﬂex coronary
artery (LCX) up to the junction of the middle and distal thirds
of the vessel, the proximal third of the major obtuse marginal
branch of the LCX, the right coronary artery (RCA) up to and
including the origin of the posterior descending coronary
artery (PDA), and the proximal third of the PDA. In cases
in which the PDA was supplied by the LCX vessel (LCXdominance), lesions in the LCX up to the origin of the PDA
were included, as were lesions of the RCA up to the origin
of the middle and distal thirds of the vessel. The PDA was
scored identically for RCA and LCX dominant circulations.
The percentage by which each lesion in the proximal coronary
circulation narrowed the artery was assessed according to the
maximal narrowing of the diameter of the artery in all projec-
tions. The severity of the proximal coronary disease was as-
sessed by assigning points to each lesion as follows: less than
50% stenosis of the luminal diameter, 1 point; 50% to 74%
stenosis, 2 points; 75% to 99% stenosis, 3 points; total
obstruction, 4 points. The points for each lesion in the proxi-
mal coronary circulation were summed and a score for severity
of coronary atherosclerosis was obtained. In a previous study,
the coefﬁcient of variation between two angiograms analyzed
several months apart without knowledge of the previous score
was 4.9%.24
(6) Laboratory examination: Blood sampling: Ten milliliters
of fasting (12–14 h) venous blood was withdrawn from the
cubital vein of every patient within one hour before coronary
angiography. Four ml was transferred slowly into vacunated
EDTA tube for the isolation of white blood cells for genotyp-
ing. Two milliliters was transferred slowly into the vacunated
EDTA tube for measuring Glycated hemogobin (HbA1c).
Two milliliters was transferred slowly into the vacunated
EDTA tube and centrifuged for 5 min at 4000 r.p.m. The plas-
ma obtained for the determination of plasma glucose was fro-
zen at 20 C till analysis. Two milliliters was transferred
slowly into a plain tube for the determination of serum total
cholesterol, triglycerides, HDL cholesterol left for 30 min for
clotting and centrifuged for 10 min at 4000 r.p.m. The serum
was obtained frozen at 20 C till analysis. Blood glucose,
HbA1c, serum cholesterol, triglycerides and HDL cholesterol
were determined by enzymatic colorimetric test. LDL choles-
terol was estimated by Friedewald’s formula.25
Leukocyte isolation: Leukocytes were isolated from the
whole blood by removing erythrocytes by suspending cells in
8 ml erythrocyte lysing buffer (ELB), then centrifuged for
5 min at 1000 rpm. Centrifugation was repeated twice more till
a white pellet appeared. Carefully, the blood platelets were re-
moved and the white pellet washed twice with 1 ml phosphate
buffer solution (PBS) and then transferred to Eppendorf tubes
for next step DNA extraction.26
DNA extraction: By Using QIAamp DNA Blood Mini
Kits (QIAGEN HILDEN, Germany).
Paraoxinase 192 genotyping: The ampliﬁcation reaction for
Gln192–Arg was performed in 25 ll volumes (10 ll DNA tem-
plate + {15 ll Master Mix containing 2.5 ll of 10· PCR buf-
fer, 0.25 ll MgCl 25 mM, 1.0 ll dNTPs 10 mM, 1.0 ll forward
primer (F50-TAT TGT TGC TGT GGG ACC TGA G-30),
1.0 ll reverse primer (R50-CAC GCT AAA CCC AAA TAC
ATC TC -30), 0.5 ll Taq polymerase 5 lm/ll and 8.75 ll dis-
tilled water}. Using an initial denaturation (5 min at 95 C),
followed by 35 cycles each consisting of {denaturation (1 min
at 95 C), annealing (1 min at 61 C), extension (1 min at
72 C) } and ﬁnal extension (10 min at 72 C) using Perkin
Elmer thermal cycler 2400 (USA).27
Identiﬁcation of the Gln192–Arg polymorphism: The PON1 192
(99 bp) PCR product was digested with AlwI at 37 C for 3 h
(2 ll 10· buffer, 1 ll AlwI, 7 ll distilled water and 10 ll PCR
product). The AlwI digestive products were run by 5% poly-
acrylamide gel electrophoresis for 30 min and stained with
Figure 1 PCR products yielded 99-bp bands.
Figure 2 Arg/Arg: 66 and 33 bp; Gln/Gln: 99 bp; Arg/Gln: 99,
66 and 33 bp. Lane (1) DNA ladder 50 bp; Lane (2, 3 and 8) all
three bands in Arg/Gln heterozygotes; Lane (4, 5 and 7) Arg/Arg
homozygotes 33 and 66-bp bands; Lane (6, 9 and 10) Gln/Gln
homozygotes 99-bp bands.
58 M.F. Elnoamany et al.ethidium bromide, and the bands were visualized under ultra-
violet light. Digested PCR products yielded 99-bp bands in
Gln/Gln homozygotes, 66 and 33-bp bands in Arg/Arg homo-
zygotes, and all three bands in Arg/Gln heterozygotes (Figs. 1
and 2).27Table 1 Baseline demographic, clinical and laboratory characterist
Items Group I (n= 40) Group II (n
Age (years) 50.19 ± 5.5 51.11 ± 6.7
Sex (male/female) 30/10 33/12
BMI (kg/m2) 24.9 ± 3.9 25.7 ± 4.1
Smoking (%) 44.9 47.1D
Systolic blood pressure (mmHg) 130.9 ± 22.1 136.3 ± 19
Diastolic blood pressure (mmHg) 75.4 ± 13.2 79.12 ± 11
LVEF (%) 70.1 ± 11.4 68.9 ± 9.16
LVMI (g/m2) 99 ± 29 105 ± 25
HbA1c (%) 5.4 7.9
*
Total cholesterol (mg/dl) 192.3 ± 25.6 209.11 ± 1
Triglycerides (mg/dL) 135.5 ± 18.3 170.33 ± 2
HDL cholesterol (mg/dL) 45.3 ± 5.2 37.7 ± 7.11
LDL cholesterol (mg/dL) 120.2 ± 14.4 135.3 ± 15
BMI, body mass index; LVEF, left ventricular ejection fraction; LVMI, l
density lipoproteins; LDL, low-density lipoproteins; NS, nonsigniﬁcant.
* Group I vs. other groups.
# Group II vs. other groups.
D Group IV vs. other groups.4. Statistical analysis
Data were analyzed by SPSS statistical package version 11.0
(SPSS Inc., Chicago, IL, USA). Quantitative data were ex-
pressed as mean and standard deviation (SD). Qualitative data
were expressed as number and percentage and analyzed by
Chi-square (v2) or Fisher exact test when appropriate.
Comparisons between means were evaluated by unpaired t-
test or ANOVA (F) test (with post hoc test) for continuous
variables with determination of the least signiﬁcant difference
(LSD) by pair wise comparison between group means, and by
Chi-square test for proportions.
Multivariate logistic regression was used to assess indepen-
dent predicators of coronary artery disease among patients
using, demographic, clinical, laboratory and echocardio-
graphic variables. Level of signiﬁcance was set as p value
<0.05.28
5. Results
The study comprised 180 patients recruited from those under-
going coronary angiography for suspected CAD, who were di-
vided according to the presence or absence of CAD and DM
into four groups: Group I (n= 40 patients, 30 males and 10
females with mean age 50.19 ± 5.5 years) nondiabetic subjects
without CAD, Group II (n= 45 patients, 33 males and 12 fe-
males with mean age 51.11 ± 6.7 years) diabetic patients with-
out CAD, Group III (n= 47 patients, 34 males and 13 females
with mean age 53.33 ± 4.9 years) nondiabetic patients with
CAD and Group IV (n= 48 patients, 35 males and 13 females
with mean age 54.79 ± 6.5 years) diabetic patients with CAD.
There was no signiﬁcant difference between the studied
groups as regards the age, gender, body mass index (BMI), sys-
tolic or diastolic blood pressure, left ventricular ejection frac-
tion or left ventricular mass index.
The number of smokers was signiﬁcantly higher in Groups
III and IV compared to each of Group I and Group II. Glycat-
ed hemogobin (HbA1c) was signiﬁcantly higher in diabetic
groups (Groups II and IV) in comparison to nondiabetic
groups (Groups I and III), p< 0.05 (Table 1).ics of the studied groups.
= 45) Group III (n= 47) Group IV(n= 48) p Value
53.33 ± 4.9 54.79 ± 6.5 NS
34/13 35/13 NS
25.6 ± 3.77 26.2 ± 3.6 NS
60.3*,# 65.7* <0.05
.2 140.7 ± 23.3 141.5 ± 25.5 NS
.6 80.9 ± 13.5 83.5 ± 10.8 NS
65.7 ± 10.3 64.5 ± 8.8 NS
109 ± 19 111 ± 36 NS
5.7#,D 8.5* <0.05
9.7D 216.1 ± 22.8*,D 241.4 ± 31.9* <0.01
1.6* 155.7 ± 19.5*,#,D 180.2 ± 25.6* <0.01
*,D 33.19 ± 6.3* 30.7 ± 6.9* <0.05
.8*,D 152.9 ± 13.1*,D,# 175.7 ± 20.3* <0.001
eft ventricular mass index; HbA1c, glycated hemoglobin; HDL, high-
Table 2 Paraoxonase1 genotypes, allele frequencies and angiographic scores in the studied groups.
Items Group I (n= 40) Group II (n= 45) Group III (n= 47) Group IV (n= 48) p Value
Paraoxonase 192 genotype
Gln/Gln (type A) 25 (62.5%) 27(60%)D 18 (38.3%)*,# 15 (31.25%)* <0.001
Gln/Arg (type AB) 13 (32.5%) 14 (31.11) 15 (31.9%) 14 (29.17%) NS
Arg/Arg (type B) 2 (5%) 4 (8.89%)D 14(29.79%)*,# 19 (39.58%)* <0.001
Allele frequency
Gln/Gln (type A) 25 (62.5%) 27(60%)D 18 (38.3%)*,# 15 (31.25%)* <0.001
Arg/Arg (type B) + Gln/Arg (type AB) 15 (37.5%) 18 (40%)D 29 (61.7%)*,# 23 (68.75%)* <0.001
Severity score 0 0D 6.99±3.71*,#,D 9.7± 2.97* <0.001
Vessel score 0 0D 1.67±0.89*,#,D 2.44±0.56* <0.001
Gln, glutamine; Arg, arginine; NS, nonsigniﬁcant.
* Group I vs. other groups.
# Group II vs. other groups.
D Group IV vs. other groups.
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pared to other groups and in Group III in comparison to
Group I, while triglycerides were signiﬁcantly higher in all
groups compared to Group I and each of Group II and Group
IV in comparison to Group III, p< 0.01. HDL cholesterol
was signiﬁcantly higher in Group I in comparison to other
groups and in Group II compared to Group IV, p< 0.05.
LDL cholesterol was signiﬁcantly higher in all groups com-
pared to Group I, while it was signiﬁcantly higher in Group
IV in comparison to Groups II and III and in Group III com-
pared to Group II, p< 0.001 (Table 1).
As regard paraoxonase 1 genotype, the prevalence of Gln/
Gln (Type A) genotype was signiﬁcantly higher in Group I
and Group II compared to Group III and Group IV (62.5%,
60% vs. 38.3, 31.25%, respectively, p< 0.001). On the other
hand, the percentage of patients having Arg/Arg (type B)
genotype was signiﬁcantly higher in Group III and Group
IV in comparison to Group I and Group II (29.79%,
39.58% vs. 5, 8.89%, respectively, p< 0.001) while the per-
centage of patients having Gln/Arg (type AB) genotype did
not differ signiﬁcantly among all studied groups (Table 2).
Collectively, the frequency of Gln allele (type A) was signif-
icantly higher in Groups I and II compared to Groups III and
IV while the frequency of Arg allele (type B + type AB) was
signiﬁcantly higher in ischemic groups (III and IV) compared
to nonischemic groups (I and II) (61.7%, 68.75% vs. 37.5%,
40%, respectively, p< 0.001). Patients with CAD and DM
(Group IV) have signiﬁcantly higher severity score and vessel
score than those with CAD only (Group III) (9.7 ± 2.97,
2.44 ± 0.56 vs. 6.99 ± 3.71, 1.67 ± 0.89, respectively,
p< 0.001) (Table 2).
There were no signiﬁcant differences between carriers of the
Arg allele (type B + type AB) and those homozygous for GlnTable 3 Paraoxonase 1 allele frequencies in different vessel scores a
Items Vessel score
0 (n= 85) 1 (n= 2
Severity score 0 3.11 ±
Gln/Gln (type A) 61 (71.77%) 12 (46.1
Arg/Arg (type B) + Gln/Arg (type AB) 24 (28.23%) 14 (53.8
Gln, glutamine; Arg, arginine.allele (type A) with respect to age, gender, smoking , body
mass index, systolic or diastolic blood pressure, plasma choles-
terol, triglycerides.
Patients with vessel score 3 had signiﬁcantly higher severity
score and higher Arg allele frequency than patients with vessel
score 2, the latter group had also signiﬁcantly higher severity
score and Arg allele frequency than patients with vessel score
1 (8.9 ± 2.79 vs. 5.21 ± 2.13 and 80.49% vs. 67.86%),
(5.21 ± 2.13 vs. 3.11 ± 0.89 and 67.86% vs. 53.85 %),
p< 0.001 for all (Table 3).
In multivariate logistic regression analysis of different vari-
ables for the prediction of CAD, age [OR 2.99, CI (1.11–10.5),
p< 0.01], smoking [OR 4.13, CI (1.37–11.7), p< 0.001], LDL
cholesterol > 100 mg/dL [OR 4.31, CI (1.25–12.5), p< 0.001],
HDL cholesterol < 40 mg/dL [OR 5.11, CI (1.79–16.33),
p< 0.001] and paraoxonase 192 Arg allele [OR 4.62, CI
(1.67–13.57), p< 0.001] were signiﬁcantly independent predic-
tors of CAD (Table 4).
6. Discussion
Peroxidation of low-density lipoproteins (LDL) plays a central
pivotal role in atherogenesis.29 Enzymes associated with HDL
particles, including paraoxonase 1, platelet-activating factor
acyltransferase and lecitin-cholesterol acyltransferase (LCAT),
can cleave oxidized lipids from LDL. High-density lipopro-
teins (HDL) diminish the accumulation of lipid peroxides in
LDL mainly due to paraoxonase activity.30
The present study was designed to investigate the relation-
ship between PON1 gene polymorphism and the presence, ex-
tent and severity of CAD in type 2 DM. In our study, the
frequency of Gln allele (type A) was signiﬁcantly higher in
Groups I and II compared to Groups III and IV while thend severity scores.
F-test p Value
6) 2 (n= 28) 3 (n= 41)
0.89 5.21 ± 2.13 8.9 ± 2.79 58.7 <0.001
5%) 9 (32.14%) 8 (19.51%) 65.3 <0.001
5%) 19 (67.86%) 33 (80.49%) 72.14 <0.001
Table 4 Multivariate regression analysis of predictors of
coronary artery disease in the studied populations.
Items Presence of CAD p Value
OR 95% CI
Age (years) 2.99 1.11–10.5 <0.01
Sex (male/female) 1.27 0.52–3.9 NS
Smoking 4.13 1.37–11.7 <0.001
BMI 1.77 1.15–4.99 NS
Hypertension 2.79 1.95–4.11 NS
HbA1c (%) 2.53 1.19–6.13 NS
Diabetes duration 0.97 0.33–3.22 NS
LDL cholesterol >100 mg/dL 4.31 1.25–12.5 <0.001
HDL cholesterol <40 mg/dL 5.11 1.79–16.33 <0.001
Paraoxonase 192 Arg allele 4.62 1.67–13.57 <0.001
OR, Odds ratio; CI, conﬁdence interval; BMI, body mass index;
HbA1c, glycated hemoglobin; NS, nonsigniﬁcant; Arg, arginine;
LDL, low-density lipoprotein; HDL, high-density lipoprotein.
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higher in ischemic groups (III and IV) compared to nonis-
chemic groups (I and II). To conﬁrm the causative role of
PON1 gene polymorphism in CAD and to exclude the possibil-
ity that Arg allele carriers (type B + type AB) have other risk
factors related to CAD, we investigated these risk factors be-
tween the 2 groups (type A vs. type B + type AB). There were
no signiﬁcant differences between carriers of the Arg allele
(type B + type AB) and those homozygous for Gln allele (type
A) with respect to age, gender, smoking, body mass index, sys-
tolic or diastolic blood pressure, plasma cholesterol,
triglycerides.
This observation related to the causative role of PON1 gene
polymorphism in CAD was ﬁrst reported by Ruiz et al.31 who
found the same association between the paraoxonase 192 Arg
allele and CAD in 434 French type 2 diabetic, and has recently
been conﬁrmed by Odawara et al.11 who reported a highly sig-
niﬁcant increase in AB + B genotypes in diabetic patients with
CAD compared with those without CAD. They also reported
a trend toward an increased frequency of the Arg allele in pa-
tients with CAD, although this did not reach statistical signif-
icance, presumably because of the relatively limited number of
patients they analyzed.
In agreement with our ﬁndings, Pfohl et al.10 reported that
paraoxonase 192 Arg allele was signiﬁcantly associated with
both the presence and the extent of CAD, comparing the pa-
tients with angiographically proven CAD and those without
angiographic, clinical, or ECG evidence of CAD.
In accord with our results, Jalilian et al.32 reported that Arg
allele frequency was signiﬁcantly higher in patients with CAD
than those with normal coronaries and more interestingly they
reported signiﬁcantly higher Arge allele frequency with in-
creased CAD severity.
Furthermore, James et al.33 found that the PON1 Arg
genotype was signiﬁcantly higher in diabetic patients with
CAD than diabetic patients without CAD.
Consistent with the same observations, Lavi et al.34 postu-
lated that coronary endothelial dysfunction in humans with
early coronary atherosclerosis is associated with the paraoxon-
ase 1 allelic variant 192 Arg > Gln.
Interestingly, in our study, PON 1 gene polymorphism was
associated not only with the presence of CAD but also with theextent and severity of CAD. Patients with CAD (Groups III
and IV) have signiﬁcantly higher Arg allele frequency (type
B + type AB) compared to nonischemic groups (Group I
and II). Moreover, in the subgroup analysis of patients with
CAD, we found that, patients with higher vessel score had sig-
niﬁcantly higher Arg allele frequency and signiﬁcantly higher
severity score compared to patients with lower vessel score
and these ﬁndings are more pronounced in patients with
CAD and diabetes mellitus than in patients with CAD alone.
In type 2 diabetic patients the functional role of paraoxon-
ase is more important than in nondiabetic subjects. Chronic
hyperglycemia causes considerable modiﬁcation of protein
structure and function due to nonenzymatic glycation of ami-
no acid residues,35 and LDL cholesterol containing glycated
apolipoprotein B100 interacts with vascular endothelium36
and platelets, thereby increasing thromboxane production
and decreasing thrombolytic prostaglandins.37 In addition,
glycated LDL cholesterol is more readily oxidized,38 resulting
in accelerated macrophage uptake by the scavenger receptor
pathway. It can therefore be speculated that, the protective ef-
fects of paraoxonase against peroxidation of LDL particles are
more important in diabetic patients. The difference could ex-
plain the much clearer effect of the paraoxonase 192 genotype
on CAD in type 2 diabetic patients than in general popula-
tions. This hypothesis is further supported by the results of
Pfohl et al.10 concerning subgroup analysis in current and for-
mer smokers, which supposed an even stronger association be-
tween the paraoxonase 192 Arg allele and CAD among
smokers. In accordance with diabetes, smoking is an estab-
lished risk factor for CAD in which oxidative mechanisms play
an important role. Cigarette smoke contains large amounts of
free radicals39 and plasma antioxidative capacity is lower in
smokers40,41 so oxidized LDL particles from smokers generate
more lipid peroxidation products than LDL from nonsmok-
ers.42 Thus it seems conceivable that, the paraoxonase activity
has a more important role in smokers in protecting from the
lipid peroxidation process in vivo. Plasma paraoxonase activ-
ity has recently been shown to be inhibited by cigarette smoke
extract.43
In the current study, and in multivariate logistic regression
analysis of different variables for the prediction of CAD, we
found that, age, smoking, LDL cholesterol > 100 mg/dL,
HDL cholesterol < 40 mg/dL and paraoxonase 192 Arg al-
lele were signiﬁcantly independent predictors of CAD. In
accordance to our ﬁndings, similar data reported by Pfohl
et al.10 who postulated that, age, paraoxonase 192 Arg allele,
history of smoking, hypertension, and hyperlipidemia were
signiﬁcantly associated with CAD. Furthermore they found
that, factors signiﬁcantly associated with three-vessel disease
were age, paraoxonase 192 Arg allele, BMI, and hyperten-
sion. On the other hand, Odawara et al.11 reported that only
PON1 genotype contributed to the pathogenesis of CAD in
Japanese type 2 diabetic patients, independently of other
known risk factors for CAD. Nevertheless, Lavi et al.34
found that, in the multivariable model, only paraoxonase
allelic variants remained a predictor of endothelial
dysfunction.
PON1 protects against macrophage-mediated LDL oxida-
tion, and increases HDL binding to macrophages which, in
turn, stimulates HDLs ability to promote cholesterol efﬂux.44
Macrophage cholesterol accumulation and foam cell forma-
tion are the hallmark of early atherogenesis. In addition to
Paraoxonase 1 gene (Gln192–Arg) polymorphism and the risk of coronary artery disease in type 2 diabetes mellitus 61macrophages, at least three more major players regulate
atherosclerosis development; PON1, antioxidants, and HDL.
These major anti-atherogenic properties of HDL (and of
PON1) require, at least in part, macrophage binding sites for
HDL-associated PON1.44 High-density lipoprotein (HDL)
interrupts the process of atherogenesis at several key stages.
HDL opposes atherosclerosis directly, by removing cholesterol
from foam cells, by inhibiting the oxidation of LDLs, and by
limiting the inﬂammatory processes that underlie atherosclero-
sis. Endogenous, puriﬁed, or reconstituted HDLs or HDL-
associated lysosphingolipids (sphingosylphosphorylcholine or
lysosulfatide), have been shown to inhibit the expression of
E-selectin, ICAM-1, and VCAM-1 or other adhesion mole-
cules by vascular endothelial cells exposed to cytokines. Fur-
thermore, low HDL-cholesterol levels have been shown to
correlate with elevated PAI-1, increased levels of ﬁbrinogen
and high index of platelet aggregability in humans. Accord-
ingly HDL also has antithrombotic properties.45 Indeed,
PON1, as well as HDL-associated PON1, speciﬁcally bind to
macrophages, leading to anti-atherogenic effects. Macrophage
PON1 binding sites may thus be a target for future cardiopro-
tection therapy. Studying the interactions among PON1, anti-
oxidants, and macrophages can thus assist in achieving
appropriate treatment and prevention of atherosclerosis.44
Study Limitations: Although the number of patients analyzed
was not large in our study, the highly signiﬁcant results suggest
an important role of the PON1 gene Gln192–Arg polymor-
phism in the pathogenesis of CAD but large scale studies are
strongly recommended for more validation of the results.
Another limitation we did not measure paraoxonase activity.
However, doing so might not clarify the complex causal
relationship between paraoxonase activity and early athero-
sclerosis. Furthermore, paraoxonase levels in serum might
not correlate with lipoprotein-bound paraoxonase. Genetic
associations are more likely to clarify the causal relationship.
7. Conclusion
Arg allele of PON1 192 gene polymorphism is an independent
risk factor for CAD and is associated not only with the pres-
ence of CAD but also with its extent and severity and its im-
pact is clearly more pronounced in diabetic patients.References
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